Scancell

Scancell is a pioneering clinical-stage immunotherapy biotech company dedicated to developing innovative treatments that address significant unmet needs in cancer care. Scancell's commitment lies in translating cutting-edge research and ingenuity into effective and lasting responses for patients, all while prioritizing safety and targeting cancers that are difficult to treat.

Scancell has cultivated a robust pipeline of 'off-the-shelf' vaccines designed to stimulate immune responses, along with highly tumor-specific monoclonal antibodies that redirect immune cells or drugs precisely where they are needed. Scancell's advanced therapeutic vaccine programs, SCOPE and ModiFY, have demonstrated encouraging efficacy in Phase 2 trials, showcasing the potential for long-term survival in patients with metastatic melanoma and a diverse array of solid tumors. The primary address for Scancell is in Oxford, GB, with an additional location in Nottingham, GB.

With a focus on innovation and patient outcomes, Scancell is poised to make a significant impact on the future of cancer treatment. Scancell continues to push the boundaries of immunotherapy, offering hope for improved outcomes and enhanced quality of life for patients worldwide. We invite the management team at Scancell to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.